98%
921
2 minutes
20
Estimated glomerular filtration rate (eGFR) is adjusted for Black race in commonly used formulas. This has potential implications for access to simultaneous liver-kidney transplantation (SLKT) as qualifying criteria rely on eGFR. We performed a retrospective study of United Network for Organ Sharing national transplant registry data between February 28, 2002, and March 31, 2019, to evaluate the proportion of Black patients who would be reclassified as meeting SLKT criteria (as defined per current policies) if race adjustment were removed from 2 prominent eGFR equations (Modification of Diet in Renal Disease-4 [MDRD-4] and Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]). Of the 7937 Black patients listed for transplant during the study period, we found that 3.6% would have been reclassified as qualifying for chronic kidney disease (CKD)-related SLKT with removal of race adjustment for MDRD-4, and 3.0% would have been reclassified with CKD-EPI; this represented 23.7% and 18.7% increases in SLKT candidacy, respectively. Reclassification impacted women more than men (eg, 4.5% versus 3.0% by MDRD-4; P < 0.05). In an exploratory analysis, patients meeting SLKT criteria by race-unadjusted eGFR equations were significantly more likely to receive liver transplantation alone (LTA) compared with SLKT. Approximately 2.0% of reclassified patients required kidney transplantation within 1 year of LTA versus 0.3% of nonreclassified patients. In conclusion, race adjustment in eGFR equations may impact SLKT candidacy for 3.0% to 4.0% of Black patients listed for LTA overall. Approximately 2.0% of patients reclassified as meeting SLKT criteria require short-term post-LTA kidney transplantation. These data argue for developing novel algorithms for glomerular filtration rate estimation free of race to promote equity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943444 | PMC |
http://dx.doi.org/10.1002/lt.26310 | DOI Listing |
J Clin Endocrinol Metab
September 2025
AURA (Association pour l'Utilisation du Rein Artificiel dans la région parisienne), F-75014 Paris, France.
Purpose: Obesity is an independent risk factor for chronic kidney disease, and accurate estimation of the glomerular filtration rate (GFR) is crucial. However, limited data are available on the performance of the European Kidney Function Consortium (EKFC) equation in individuals with overweight or obesity. We evaluated the performance of the EKFC equation by comparing its estimated GFR (eGFR) to values obtained from the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and machine learning (ML) models, using measured GFR (mGFR, obtained via plasma iohexol clearance) as a reference standard in a cohort of patients with overweight or obesity.
View Article and Find Full Text PDFEcotoxicol Environ Saf
September 2025
Department of Nephrology, Chang Gung Memorial Hospital, Keelung Branch, 222, Mai-Chin Road, Keelung 20401, Taiwan; College of Medicine, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan Dist, Taoyuan City, Taipei 33302, Taiwan; Community Medicine Research Center, Chang Gung Memorial Hospital,
Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic chemicals widely used in industrial and consumer applications, known for their environmental persistence, bioaccumulation, and potential toxicity. Mounting toxicological evidence suggests that the kidney is a primary target organ for PFAS accumulation, yet human data regarding compound-specific renal effects remain limited. In this community-based prospective cohort study, we investigated the associations between serum PFAS concentrations and renal outcomes in 257 adults, including 48 with chronic kidney disease (CKD) and 209 with normal kidney function at baseline.
View Article and Find Full Text PDFArq Bras Cardiol
September 2025
Escola Bahiana de Medicina e Saúde Pública, Salvador, BA - Brasil.
Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.
Objective: To determine the risk factors for valvular calcification in patients with CKD.
Clin J Am Soc Nephrol
September 2025
The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Background: Substantial advances have been made in therapeutics for IgA nephropathy. We conducted a systematic review and meta-analysis to evaluate the comparative efficacy and safety of existing and novel IgA nephropathy therapies.
Methods: We searched MEDLINE and Embase databases from inception to May 21, 2025 for Phase 2b and 3 multi-center, randomized, placebo-controlled trials enrolling patients with IgA nephropathy that reported treatment effects on proteinuria and/or estimated glomerular filtration rate (eGFR) slope.
MedComm (2020)
September 2025
Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis globally, is characterized by mesangial IgA deposition and heterogeneous clinical trajectories. Historically, management relied on renin-angiotensin system inhibition and empirical immunosuppression, yet high lifetime kidney failure risk persists despite optimized care. This review synthesizes advances in molecular pathogenesis, highlighting how the traditional multi-hit hypothesis-while foundational for targeted therapy development-fails to capture IgAN's recurrent, self-amplifying nature.
View Article and Find Full Text PDF